Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Balk

Showing results (131-140 of 189) with videos related to

Pageof 19
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2026
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerNicole A Traphagen, Esmé Wheeler, Rong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2016
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate CancerShuai Gao, Huihui Ye, Sean Gerrin, et al.
Cancer Research|March 5, 2020
<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerShahrzad Rafiei, Kenyon Fitzpatrick, David Liu, et al.
Cancers|August 27, 2021
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate CancerEdoardo Francini, Fang-Shu Ou, Justin Rhoades, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinaseWooyoung Hur, Anastasia Velentza, Sungjoon Kim, et al.
Cancer Research Communications|September 4, 2023
Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer ProgressionAnna Besschetnova, Wanting Han, Mingyu Liu, et al.
Cancer Research|March 27, 2015
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapyChen-Lin Hsieh, Ginevra Botta, Shuai Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate CancerElahe A Mostaghel, Brett T Marck, Orpheus Kolokythas, et al.
Nature Communications|December 16, 2021
Androgen receptor and MYC equilibration centralizes on developmental super-enhancerHaiyang Guo, Yiming Wu, Mannan Nouri, et al.
The Journal of Urology|August 19, 2014
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cellsJi Lu, Peter E Lonergan, Lucas P Nacusi, et al.
Pageof 19

Showing results (131-140 of 189) with videos related to

Sort By:
Pageof 19
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2026
Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancerNicole A Traphagen, Esmé Wheeler, Rong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2016
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate CancerShuai Gao, Huihui Ye, Sean Gerrin, et al.
Cancer Research|March 5, 2020
<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerShahrzad Rafiei, Kenyon Fitzpatrick, David Liu, et al.
Cancers|August 27, 2021
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate CancerEdoardo Francini, Fang-Shu Ou, Justin Rhoades, et al.
Bioorganic & Medicinal Chemistry Letters|August 1, 2008
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinaseWooyoung Hur, Anastasia Velentza, Sungjoon Kim, et al.
Cancer Research Communications|September 4, 2023
Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer ProgressionAnna Besschetnova, Wanting Han, Mingyu Liu, et al.
Cancer Research|March 27, 2015
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapyChen-Lin Hsieh, Ginevra Botta, Shuai Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate CancerElahe A Mostaghel, Brett T Marck, Orpheus Kolokythas, et al.
Nature Communications|December 16, 2021
Androgen receptor and MYC equilibration centralizes on developmental super-enhancerHaiyang Guo, Yiming Wu, Mannan Nouri, et al.
The Journal of Urology|August 19, 2014
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cellsJi Lu, Peter E Lonergan, Lucas P Nacusi, et al.
Pageof 19